Detalles de la búsqueda
1.
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
J Antimicrob Chemother
; 77(9): 2522-2531, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781341
2.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022730
3.
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Crit Care
; 26(1): 373, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36457059
4.
Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
Clin Infect Dis
; 73(9): e2616-e2624, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32735653
5.
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Crit Care
; 25(1): 354, 2021 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34600585
6.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Crit Care
; 25(1): 290, 2021 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380538
7.
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Antimicrob Agents Chemother
; 64(12)2020 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32988827
8.
Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
J Antimicrob Chemother
; 73(9): 2524-2528, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29788418
9.
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
J Thorac Oncol
; 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642841
10.
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Microbiol Spectr
; 12(3): e0356323, 2024 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38299867
11.
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Ann Intensive Care
; 13(1): 8, 2023 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36773112
12.
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
Open Forum Infect Dis
; 10(6): ofad225, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37383243
13.
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
J Clin Oncol
; 41(11): 1999-2006, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36735893
14.
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
J Clin Oncol
; 41(11): 1992-1998, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809080
15.
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Eur Urol Oncol
; 5(2): 225-234, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34244116
16.
Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.
Open Forum Infect Dis
; 8(1): ofaa629, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33511241
17.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
J Clin Oncol
; 39(21): 2339-2349, 2021 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33872070
18.
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
Eur J Cancer
; 157: 391-402, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34571336
19.
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
J Thorac Oncol
; 16(10): 1718-1732, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34048946
20.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
J Immunother Cancer
; 9(4)2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33879601